Latest Breaking News On - Simcere pharmaceutical group ltd - Page 6 : comparemela.com

Vivoryon Therapeutics N V : Vivoryon Therapeutics Provides Update on Financial Guidance

About Vivoryon Therapeutics N.V. Vivoryon is a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the live of medically underserved patients suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings before they cause irreversible damage. Beyond our lead program, varoglutamstat, which is in Phase 2 clinical development to treat Alzheimer s disease, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis. www.vivoryon.com

Sophia hergenhanManuela baderTrophic communicationsSimcere pharmaceutical group ltdVivoryon therapeutics provides updateEuronext amsterdamSimcere pharmaceutical group

Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and C

Search jobs 28-Jun-2021 Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and Commercialize N3pE Amyloid-targeting Medicines to Treat Alzheimer s Disease in Greater China DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Agreement 29.06.2021 / 01:03 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and Commercialize N3pE Amyloid-targeting Medicines to Treat Alzheimer s Disease in Greater China Halle (Saale)/Munich, Germany and Nanjing, China, June 29, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines and Simcere Pharmaceutical Group Ltd (HKEX: 2096) (Simcere) today announced that they have entered into a strategic regional licensin

Ekevin oliverJason baoSophia hergenhanManuela baderMichael schaefferSimcere announce strategic regional licensing partnership toHead of global business development at simcereSimcere pharmaceutical groupTrophic communicationsSimcere pharmaceutical group ltdDistribution servicesTreat alzheimerEuronext amsterdamGreater chinaChief businessSenior vice president

DGAP-News: Vivoryon Therapeutics N V : Vivoryon Therapeutics Provides Update on Financial Guidance

DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Financial Guidance vom 29.06.2021, 01:11 Uhr Bild: pixabay.com Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Financial Guidance 29.06.2021 / 01:11 Vivoryon Therapeutics Provides Update on Financial Guidance Halle (Saale) / Munich, Germany, June 29, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines, today announced an update on its financial guidance. According to current estimates, the Company expects the recently signed regional licensing agreement with Simcere Pharmaceutical Group Ltd. to have an impact on Vivoryon s previously communicated cash-reach of Q3 2022, which is anticipated to be extended for at least three quarters until Q2 2023. A detailed update on anticipated working capital requirements and resulting timelines will be giv

Noord hollandHalle saaleSophia hergenhanManuela baderNews serviceTrophic communicationsSimcere pharmaceutical group ltdDistribution servicesVivoryon therapeutics provides updateFinancial guidanceTherapeutics provides updateEuronext amsterdamSimcere pharmaceutical groupCorporate newsRegulatory announcementsUnofficial market

Kazia Therapeutics Ltd lands trifecta of licensing deals in March quarter, leaving it a vastly stronger and more substantial business

Kazia Therapeutics lands trifecta of licensing deals in March quarter, leaving it a vastly stronger and more substantial business During the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million end-March. These transactions leave Kazia a vastly stronger and more substantial business, with a diversified pipeline of world-class oncology assets. Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) has kicked off 2021 with a trifecta of March quarter licensing deals, leaving it a vastly stronger and more substantial business , according to CEO Dr James Garner. During the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million by the end of March.

Hong kongSimcere pharmaceuticalSimcere pharmaceutical group ltdOasmia pharmaceuticalGreater chinaஹாங் காங்அதிகமானது சீனா

Kazia Therapeutics Ltd lands trifecta of licensing deals in March quarter, leaving it a vastly stronger and more substantial business

Kazia Therapeutics Ltd lands trifecta of licensing deals in March quarter, leaving it a vastly stronger and more substantial business
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

Hong kongSimcere pharmaceuticalSimcere pharmaceutical group ltdOasmia pharmaceuticalGreater chinaஹாங் காங்அதிகமானது சீனா